GENERAL INFORMATION
Established:  2005
Ownership:  Private

Core business

Interventional cardiology. Developer of a solution for the next
generation of stents.

Employees:  34
Main Markets:  Interventional Cardiologists.

Overview

INSPIREMD LTD. was founded in 2005 by three entrepreneurs having
a wide range of expertise.
INSPIREMD LTD. is an innovative medical device company focusing
on the development and commercialization of its proprietary stent
platform technology, MGuard. The company proprietary technology
was invented to provide embolic protection in stenting procedures
by placing a proprietarily designed mesh sleeve over a bare metal
stent.

The company intends to apply its technology to develop products
used in interventional cardiology and other vascular procedures.

The MGuard Coronary stent presents a novel combination of a
coronary stent merged with an embolic protection device. The
embolic protection device is comprised of an ultra-thin polymer
mesh protective sleeve, wrapped around the stent. The protective
sleeve is composed of a micron-level-fiber knitted mesh,
engineered in an optimal geometric configuration and designed for
utmost flexibility while retaining strength characteristics of
the fiber material. The sleeve is designed to expand seamlessly
when the stent is deployed, without affecting the structural
inTEGRITY of the stent, and to prevent plaque detachment during
and post procedure. The MGuard Coronary stent provides long
acting embolic protection, without adding complexity in
deliverability. The sleeve is designed to diffuse stent pressure
on the vessel wall, thereby may reduce injury and lower the
likelihood of restenosis.

In October 2007, the Company's first generation product, the
Guard Coronary received CE Mark for treatment of coronary
arterial disease, and clinical trial results to date have proven
safety and efficacy. The Company began shipping its product to
customers in Europe, Asia and Latin America. The MGuard
Coronary's innovative concept has enjoyed an enthusiastic welcome
from leading interventional cardiologists around the world.

INSPIREMD's mission is to utilize its proprietary technology to
make its products the industry standard for stents and to provide
a superior solution to the key clinical issues of current
stenting procedures: restenosis, embolic showers, and late
thrombosis. The Company believes that it is well positioned to
develop its next generation coronary and carotid stents and
emerge as a leading player in the global stent market by 2009.

In addition to providing embolic protection and minimizing
arterial injury, this promising technology is aimed at providing
an effective and uniform drug delivery mechanism for next
generation drug eluting stents. INSPIREMD intends to pursue
applications of this technology both for bare metal and drug
eluting stents in coronary, carotid and peripheral artery
procedures.